CS Diagnostics Corp. Launches Regulation D, Rule 506(c) Investment Offering

CHEYENNE, WYOMING / ACCESS Newswire / October 13, 2025 / CS Diagnostics Corp. (OTCQB:CSDX) today announced the official launch of its Regulation D, Rule 506(c) investment offering (the "Offering"), marking an important milestone in the company's ongoing mission to enhance patient safety and health outcomes through advanced medical technologies.

CS Diagnostics Corp. is a global medical technology company dedicated to innovation in healthcare safety and performance. The company's core products include:

• CS Protect Hydrogel - a next-generation tissue spacer gel designed to improve precision and reduce complications in radiotherapy.

• MEDUSA - a proprietary advanced surface disinfectant system that delivers effective and scalable infection control for clinical and industrial environments.

Offering Overview

The Offering is open exclusively to U.S. accredited investors and all other non-U.S. investors, providing the opportunity to participate in CS Diagnostics Corp.'s growth through the purchase of CSDX Preferred C Shares.

Proceeds from the Offering will support the commercialization and scaling of CS Protect Hydrogel and MEDUSA, advancing the company's efforts toward broad regulatory approval, global market deployment, and sustainable profitability.

This Offering structure enables investors to align with a high-growth MedTech enterprise, combining traditional equity potential with participation in a company committed to regulatory compliance, transparency, and long-term value creation.

Use of Proceeds

Net proceeds from the Offering are expected to be allocated approximately as follows:

Purpose	Allocation (Approx.)	Description
Regulatory & filing costs (U.S.)	~20-25 %	FDA / EPA / patent filings, third-party consulting, legal advisory fees, and regulatory compliance marketing.
Manufacturing scale-up & quality control	~15-20 %	Building production capacity, supplier agreements, QA/QC systems, and compliance with global safety standards.